Post Market Surveillance Study to Confirm Safety and Performance of Silicone PHMB Foam
Post Market Surveillance Study to Confirm Safety and Performance of Silicone PHMB Foam
Post market surveillance study to confirm the safety and performance of Silicone Subcategory
 of PHMB Foam Dressings in Chronic and Acute Wounds.
The design of the study is an open label, multicentre, single arm trial with subjects with
 moderate to heavily exuding chronic and acute wounds consisting of pressure ulcers, leg
 ulcers, diabetic leg and foot ulcers, surgical wounds first degree superficial and partial
 thickness burns. The performance data from this study will support clinically meaningful
 rates of successful improvement in the signs and symptoms of infection, without refection
 during 6- week treatment and follow up period.
Inclusion Criteria:

 -  Have a pressure ulcer, leg ulcer, diabetic leg and foot ulcer, surgical wound, first
 degree superficial burns or partial thickness second degree burns that are infected
 following assessment of signs and symptoms of infection with moderate to heavy levels
 of exudate.

 -  Have wounds at high risk of infection.

 -  Males or females, age 18 years or above.

 -  Subjects who are able to understand and give informed consent to take part in the
 study.

 Exclusion Criteria:

 -  Subjects who are known to be non compliant with medical treatment.

 -  Subjects who are known to be sensitive to any of the device components, known
 sensitivity to PHMB.

 -  Subject is pregnant or actively breastfeeding.

 -  Subject has any significant or unstable medical or psychiatric condition, that in the
 opinion of the investigator, would interfere with his/her ability to participate in
 the study.

 -  Subject is currently in another clinical study.

 -  Patients who have a current illness or condition, or who have had an illness in the
 last 30 days which in the opinion of the investigator may interfere with wound healing
 (e.g. carcinoma, connective tissue disease, autoimmune disease or alcohol or drug
 abuse).

 -  Life expectancy of <6 months.

 -  Maximum burn area of >20% total body area in adults.